Group 1 - The company announced the holding of its first extraordinary general meeting of shareholders in 2025 on August 18, 2025 [2] - The meeting will review and approve the "2025 Half-Year Profit Distribution Plan" [2]

证券代码：301211 证券简称：亨迪药业 公告编号：2025-035 湖北亨迪药业股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大遗漏。 特别提示： 1、本次股东大会没有出现否决议案的情况； 2、本次股东大会不涉及变更以往股东大会已通过决议的情况； 3、本次股东大会以现场与网络投票相结合的方式召开。 一、会议召开和出席的情况 （一） 会议召开情况 1、会议召开时间： 本次股东大会的召集、召开符合有关法律、行政法规、部门规章、 规范性文件和公司章程等的规定。 （二）会议出席情况 1、出席会议的总体情况 本次会议现场出席及网络出席的股东和股东代表共 143 人，代表 股份 193,095,220 股，占公司有表决权股份总数的 67.0470％。 2、现场会议出席情况 （1）现场会议召开时间：2025 年 8 月 18 日（星期一）下午 14:00 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投 票的具体时间为：2025 年 8 月 18 日上午 9:15-9:25，9:30-11:30， 下午 13:00 ...

上海市锦天城（武汉）律师事务所 关于湖北亨迪药业股份有限公司 二○二五年第一次临时股东大会的 地址：武汉市江汉区云霞路 187 号民生金融中心 8 层 03-05 电话：027-83828888 邮编：430030 上海市锦天城（武汉）律师事务所 法律意见书 上海市锦天城（武汉）律师事务所 关于湖北亨迪药业股份有限公司 法律意见书 法律意见书 二○二五年第一次临时股东大会的 致：湖北亨迪药业股份有限公司 上海市锦天城（武汉）律师事务所（以下简称"本所"）接受湖北亨迪药业 股份有限公司（以下简称"公司"）委托，委派本律师通过远程视频方式出席公 司二○二五年第一次临时股东大会（以下简称"本次股东大会"）。本律师根据《中 华人民共和国公司法》（以下简称《公司法》）等法律、法规、规章和其他规范性 文件以及《湖北亨迪药业股份有限公司章程》（以下简称《公司章程》）的有关规 定，出具本法律意见书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责，遵循了勤勉尽责和诚实信用原则，对本次股东大会所涉及的相关事 项进行了必要的核 ...

Core Viewpoint - Hubei Hendi Pharmaceutical Co., Ltd. reported a decline in revenue and net profit for the first half of 2025, primarily due to decreased sales of its main product, ibuprofen [1][3]. Group 1: Financial Performance - In the first half of 2025, the company achieved revenue of 235 million yuan, a year-on-year decrease of 2.93% [1]. - The net profit attributable to shareholders was 18.55 million yuan, down 72.92% year-on-year [1]. - For the full year of 2024, revenue was 446 million yuan, a decline of 32.75%, and net profit was 91.55 million yuan, down 48.02% [3]. Group 2: Product and Market Challenges - The decline in revenue is attributed to reduced sales of ibuprofen, intensified international market competition, and low pricing [3][4]. - Ibuprofen has historically contributed approximately 80% of the company's total revenue, making it critical to the company's performance [4]. Group 3: Research and Development - The company's R&D expenses have been decreasing, with 32.94 million yuan in 2024 and 15.88 million yuan in the first half of 2025, representing declines of 37.59% and 17.72% respectively [4]. - The reduction in R&D investment may impact future product innovation and market competitiveness [4]. Group 4: Strategic Adjustments - In response to performance pressures, the company is adjusting its fundraising projects, reducing the planned production capacity of raw materials from 1200 tons to 700 tons [5][6]. - The company plans to invest 332 million yuan in a high-end pharmaceutical formulation internationalization project, using both raised and self-owned funds [6]. - The decision to terminate the 5000-ton ibuprofen raw material project was based on market saturation and low pricing in the global market [6][7].

证券日报网讯亨迪药业（301211）8月4日在互动平台回答投资者提问时表示，截至2025年7月31日，公 司股东户数为18153户。 ...

Core Viewpoint - Hendi Pharmaceutical (301211.SZ) reported a decline in revenue and net profit for the first half of 2025, indicating ongoing financial challenges for the company [1] Financial Performance - For the first half of 2025, the company achieved operating revenue of 235 million yuan, a year-on-year decrease of 2.93% [1] - The net profit attributable to shareholders was 18.55 million yuan, down 72.92% year-on-year [1] - The net profit after deducting non-recurring gains and losses was 4.42 million yuan, a decline of 93.21% year-on-year [1] - The net cash flow from operating activities was 8.40 million yuan, down 73.71% year-on-year [1] - In 2024, the company reported operating revenue of 446 million yuan, a decrease of 32.75% year-on-year [1] - The net profit attributable to shareholders for 2024 was 91.55 million yuan, down 48.02% year-on-year [1] - The net profit after deducting non-recurring gains and losses for 2024 was 72.95 million yuan, a decline of 57.14% year-on-year [1] - The net cash flow from operating activities for 2024 was 96.07 million yuan, down 29.91% year-on-year [1] IPO and Fundraising - The total amount raised from the initial public offering (IPO) was 1.548 billion yuan, with a net amount of 1.401 billion yuan, exceeding the original target by 210 million yuan [2] - The company initially planned to raise 1.19 billion yuan for various projects, including the production of ibuprofen and other active pharmaceutical ingredients [2] - The IPO expenses amounted to 147 million yuan, with underwriting fees of 132 million yuan [2] Stock Actions - On May 24, 2023, the company announced a stock bonus plan of 2 shares for every 10 shares held, along with a pre-tax dividend of 4 yuan [3] - On August 1, 2025, the company announced a new stock bonus plan of 4.5 shares for every 10 shares held [4]

Financial Performance Summary - The company reported total revenue of 235 million yuan for the first half of 2025, a decrease of 2.93% year-on-year [1] - The net profit attributable to shareholders was 18.55 million yuan, down 72.92% compared to the previous year [1] - The gross profit margin was 21.9%, reflecting a significant decline of 39.16% year-on-year [1] - The net profit margin decreased to 7.9%, down 72.1% from the previous year [1] - The total of selling, administrative, and financial expenses amounted to 26.98 million yuan, accounting for 11.49% of revenue, an increase of 334.54% [1] Key Financial Metrics - Revenue for 2024 was 242 million yuan, compared to 235 million yuan in 2025 [1] - The net profit for 2024 was 68.50 million yuan, while it dropped to 18.55 million yuan in 2025 [1] - The cash and cash equivalents decreased by 47.18% to 540 million yuan [1] - The company's earnings per share fell to 0.06 yuan, a decrease of 75% year-on-year [1] Expense Analysis - Selling expenses increased by 13.2% due to heightened sales efforts [2] - Financial expenses surged by 85.51% primarily due to reduced interest income [3] - Research and development expenses decreased by 17.72% as fewer projects were initiated compared to the previous period [4] Cash Flow Insights - Net cash flow from operating activities decreased by 73.71% due to reduced interest income [4] - Net cash flow from investing activities increased by 109.22% as fewer large certificates of deposit were purchased [4] - Net cash flow from financing activities rose by 47.33% due to a reduction in dividend distribution compared to the previous year [4] Company Strategy and Future Plans - The company currently has no plans for share buybacks, but will disclose any future plans in accordance with regulations [5]

Core Viewpoint - Hendi Pharmaceutical (301211) reported significant declines in revenue and profit for the first half of 2025, indicating substantial operational pressure and a need for cost optimization to restore profitability [2][6]. Financial Performance Overview - Total revenue for Hendi Pharmaceutical was 235 million yuan, a year-on-year decrease of 2.93% - Net profit attributable to shareholders was 18.55 million yuan, down 72.92% year-on-year - Non-recurring net profit was 4.42 million yuan, a decline of 93.21% year-on-year - In Q2, total revenue was 120 million yuan, an increase of 15.91% year-on-year, but net profit was 8.22 million yuan, down 73.58% year-on-year [2]. Profitability Analysis - The company's gross margin was 21.9%, a decrease of 39.16% year-on-year - Net margin was 7.9%, down 72.1% year-on-year - Earnings per share were 0.06 yuan, a reduction of 75.0% year-on-year, indicating a significant drop in overall profitability despite revenue recovery in Q2 [3]. Expense Control and Cash Flow - The ratio of operating expenses (selling, administrative, and financial expenses) to total revenue was 11.49%, an increase of 334.54% year-on-year - Selling expenses increased by 13.2%, while financial expenses rose by 85.51% - Net cash flow from operating activities was 0.03 yuan per share, a decrease of 73.71% year-on-year, primarily due to reduced interest income [4]. Main Business Composition - Revenue from non-steroidal anti-inflammatory products was 160 million yuan, accounting for 68.06% of total revenue, with a gross margin of 15.27% - Cardiovascular products generated 37.76 million yuan, representing 16.08% of total revenue, with a high gross margin of 71.83% - Other products contributed 20.81 million yuan (8.86% of total revenue) with a gross margin of 8.44% - Antitumor products generated 16.42 million yuan (6.99% of total revenue) with a negative gross margin of -11.32% [5]. Development Review and Outlook - R&D investment was approximately 15.88 million yuan, down 17.72% year-on-year - The company obtained drug registration certificates for several products and made progress on multiple projects - A subsidiary passed FDA cGMP inspections, and the company was re-certified as a high-tech enterprise - Overall, Hendi Pharmaceutical faces significant operational challenges in H1 2025, with a notable decline in performance and rising expenses impacting profitability [6].

Core Viewpoint - Hendy Pharmaceutical (301211) reported disappointing financial results for the first half of 2025, with significant declines in revenue and net profit compared to the previous year [1][3]. Financial Performance Summary - Total revenue for the first half of 2025 was 235 million yuan, a decrease of 2.93% year-on-year [1]. - Net profit attributable to shareholders was 18.55 million yuan, down 72.92% year-on-year [1]. - Gross margin fell to 21.9%, a decline of 39.16% compared to the previous year [1]. - Net margin decreased to 7.9%, down 72.1% year-on-year [1]. - The total of selling, administrative, and financial expenses reached 26.98 million yuan, accounting for 11.49% of total revenue, an increase of 334.54% year-on-year [1]. Cash Flow and Expenses - Operating cash flow per share was 0.03 yuan, a decrease of 73.71% year-on-year [1]. - The company experienced a significant increase in financial expenses, which rose by 85.51% due to reduced interest income [3]. - The net cash flow from operating activities decreased by 73.71%, attributed to lower interest income [3]. Investment and Return Metrics - The company's return on invested capital (ROIC) was 1.92%, indicating weak capital returns [4]. - Historical data shows a median ROIC of 10.31% since the company went public, suggesting better investment returns in previous years [4]. Company Strategy and Future Plans - The company currently has no plans for share buybacks, but will disclose any future plans in accordance with regulations [5][6].

Core Viewpoint - Hendi Pharmaceutical (301211) reported that as of July 31, 2025, the number of shareholders is 18,153 [1] Company Summary - Hendi Pharmaceutical has engaged with investors through an interactive platform, providing updates on shareholder numbers [1]